Northern Trust Corp Trims Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Northern Trust Corp reduced its position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 2.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 104,367 shares of the company’s stock after selling 2,573 shares during the quarter. Northern Trust Corp owned 0.70% of Jasper Therapeutics worth $2,231,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JSPR. JPMorgan Chase & Co. raised its position in Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after purchasing an additional 11,567 shares during the period. Rhumbline Advisers raised its position in Jasper Therapeutics by 12.6% in the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock worth $316,000 after purchasing an additional 1,652 shares during the period. Simplify Asset Management Inc. purchased a new stake in Jasper Therapeutics in the 4th quarter worth about $428,000. EntryPoint Capital LLC purchased a new position in shares of Jasper Therapeutics during the fourth quarter worth approximately $223,000. Finally, Schroder Investment Management Group purchased a new position in shares of Jasper Therapeutics during the fourth quarter worth approximately $1,237,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $4.77 on Monday. The firm’s 50 day moving average price is $4.55 and its 200-day moving average price is $10.24. Jasper Therapeutics, Inc. has a 52-week low of $3.13 and a 52-week high of $26.84. The company has a market cap of $71.65 million, a PE ratio of -1.01 and a beta of 2.74.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24). On average, analysts forecast that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on JSPR shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Oppenheimer reduced their target price on shares of Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a research report on Thursday, May 15th. Finally, UBS Group reduced their target price on shares of Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $62.22.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.